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Case Two: Six medications were intervened upon by MTM call
center pharmacists after a patient’s medication history was
reviewed. Speciﬁc interventions accepted by the prescriber
included: combining multiple medications to a single medication
for the purpose of decreasing pill load and discontinuing med-
ication due to duplicate therapy. Assuming all medications were
maintenance medications and the patient would be in full com-
pliance with the recommended medications for the next 12
months, the total pharmacy saving for this case would be $1,019
per year.
Case Three: A patient was identiﬁed as HIV positive through drug
inference and conﬁrmed by the physician. MTM call center phar-
macists recommended adding an NRTI in accordance with
national guidelines. MTM pharmacists also noticed the patient
was noncompliant with his lipid lowering therapy, Tricor, and
recommended promoting proper use of this medication. The total
added drug cost from these recommendations would be $3,695
per year. However, incorporating the NRTI into the drug therapy
could result in $10,000 per year savings in medical cost in accor-
dance with literature. In this particular case, the net savings in
overall health care expenditures could be $6,305 per year.
Overall, the WHS polypharmacy MTMP identiﬁed 359,124
Medicare Part D members eligible for the program in 2006.
However, only about 5% of the qualiﬁed members were enrolled
in the program largely due to the chosen opt-in program design.
The WHS polypharmacy MTMP provided appropriate
therapy recommendations to the patients’ physicians, addressed
compliance and persistency issues, and optimized drug therapy.
Drug therapy outcomes have been improved by ensuring efﬁcacy
and minimizing toxicities through decreasing the number of drug
conﬂicts (e.g. drug interactions, duplicate therapy). According to
literature, clinical outcomes may be improved as a consequence
of this intervention. In addition to bringing better health out-
comes, the WHS polypharmacy MTMP could also reduce both
pharmacy and medical health care expenditures.
Lessons Learned: The WHS Polypharmacy MTMP participation
rates varied by the plan design. Overwhelmingly, those plans
with a polypharmacy MTMP opt-out design had a much higher
patient participation rate in comparison to plans with an opt-in
design (82.26% vs. 4.43%). Possible reasons for the low member
participation rate in the opt-in model include members having
difﬁculties understanding the beneﬁts and opt-in invitations
being discarded with the materials that members did not see as
pertinent.
PCASE9
MANAGEMENT OF INAPPROPRIATE USE OF 
GROWTH HORMONE
Jan SA,Valderma M
Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA
Organization: Horizon Blue Cross Blue Shield of New Jersey
Problem or Issue Addressed: Inappropriate use of growth
Hormone.
Goal: The goal of the program was to identify off label use of
growth hormone.
Outcomes items used in the decision: Pharmacy and medical data
with diagnosis was used for identiﬁcation.
Implementation Strategy: Members receiving growth hormone
were identiﬁed by using Pharmacy and medical claims data. The
physicians prescribing these members were also identiﬁed. com-
munications were sent to members and Physicians who did not
meet the FDA approved criteria or the diagnosis. Based on the
responses the next step was either disconitnuation or further
investigation.
Results: We identiﬁed 78 members who received growth hormone
in the ﬁrst quarter of 2006, letters were sent to 35 members who
met the criteria of inappropriate use. This resulted in 28 blocks
and based on that the yearly savings was approx. $400,000. This
also included identifying 17 prescribers who were not using
growth hormone according to FDA approved indication and were
refered to investigation department for reviews.
Conclusions/Lessons Learned: The program was very effective
in identifying a potential problem of inapprpriate utilization and
helped the organization both clinically and ﬁnancially. integra-
tion of pharamcy and medical data provided evidence to take
measures for inappropriate utilization.
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Organization: Intermountain Healthcare, Salt Lake City.
Problem or Issue Addressed: Use of gene testing to guide war-
farin dosing.
Organization: This project is being undertaken at Intermountain
Healthcare, an integrated health care system based in Utah, coor-
dinated by its Clinical Genetics Institute (CGI), in collaboration
with researchers at the University of Washington.
Problem or Issue Addressed: Warfarin is an effective anticoagu-
lant but has signiﬁcant bleeding risk. Recently variants in two
genes, CYP2C9 and VKORC1, have been shown to have a sig-
niﬁcant impact on the pharmacokinetics and pharmacodynam-
ics of warfarin, accounting for signiﬁcant variability in effective
dose between individuals. Though determination of variants of
these genes, when performed in a timely manner, can be incor-
porated into the algorithm used to determine starting dose of
warfarin, it is not clear whether the additional resources required
provide meaningful clinical beneﬁt.
Goals: The CGI hopes to use this project as a pilot to introduce
clinically useful, cost-effective (CE) genetic testing into the Inter-
mountain system, as well as developing methods that can be used
to make coverage decisions by the system’s health plan. The
primary goal is to determine both the clinical and economic value
of adding testing for these genes into the warfarin dosing algo-
rithm, in the setting of a community-based hospital, in order to
inform decisions about the use and coverage of the testing. The
secondary goal is to use this pilot to help educate stakeholders
in the principles of cost effectiveness.
Outcomes items used in the decision: The primary endpoints are
the differences in the total cost of anticoagulation-related care,
the cost per adverse event avoided, and the cost per day within
therapeutic range.
Implementation Strategy: The intent is to use the results from the
cost effectiveness study in conjunction with the results of the clin-
ical trial, to bring the health plan decision makers together with
the delivery-side decision makers to make a coordinated deci-
sion, explicitly including local economic outcomes, about both
the use of and reimbursement for CYP2C9 and VKORC1 testing
in this setting. These efforts will be applied in the context of the
principles of process improvement and clinical decision support,
both integral parts of Intermountain’s culture, to ensure their
consistent and efﬁcient application.
Results: The study is currently underway.
Lessons Learned: Health plans will increasingly be required to
develop coverage and reimbursement policies for genetic tests,
which can present a complex balance of beneﬁts, risks, and costs.
Because sufﬁcient evidence for decision-making may not be avail-
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able, health plans in some instances may seek to develop their
own evidence. Although this can be challenging, our project pro-
vides an example of the feasibility of such an undertaking.
PCASE11
SYNAGIS 2005–2006 SEASON
Gill P, Parmar K, Jan SA
Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA
Organization: Horizon Blue Cross Blue Shield of New Jersey.
Problem or Issue Addressed: Synagis for RSV.
Goals: To assess retrospective rate of RSV hospitalization and/or
ER visit in members who were approved for Synagis for the
season and in members who were denied Synagis for the season.
Outcomes items used in the decision: Horizon criteria for Synagis
is based on the AAP guidelines for RSV.
Implementation Strategy: After the peak RSV 2005–2006 season
was over, Horizon did a retrospective analysis on all members
who requested for Synagis. We reviewed the medical data for
claims of RSV hospitalization, RSV ER visits, or RSV ofﬁce
visits. We pulled the following diagnosis: Respiratory syncytial
virus −079.6; Respiratory syncytial virus, bronchiolitis −466.11;
and Respiratory syncytial virus, pneumonia −480.1
Results: We had a total of 1028 members request for Synagis.
Out of which 338 members (32.9%) did not meet the criteria
and 690 members (67.1%) did meet the criteria. Out of the 338
members, 6 members (1.8%) had documented claim of RSV
infection. They include the following:
• 1 patient was suspected for an admission
• 1 patient was denied and 7 days after had a hospitalization
• 1 patient was denied and 12 days after had a hospitalization
• 2 patients were denied AFTER the hospitalization
• 1 patient seemed to have a RSV hospitalization
Leasons Learned: Horizon’s Synagis criteria is based on the AAP
criteria. We will continue to monitor for RSV related hospital-
ization, RSV related ER visits, and RSV related ofﬁce visits every
season.
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DETERMINING THE VALUE OF DIAGNOSTIC/GENETIC
TESTING TO INFORM HEALTH PLAN DECISION MAKING:
ONCOTYPE DX AS A CASE STUDY
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1Premera Blue Cross, Mountlake Terrace, WA, USA, 2University of
Washington, Seattle, WA, USA
Organization: Premera Blue Cross Pharmacy and Therapeutics
Committee (P&T). Premera is a 1.6 million member regional
commercial health plan in the Paciﬁc Northwest.
Problem or Issue Addressed: Need to determine medical neces-
sity criteria and appropriate cost-effective use of Oncotype DX,
a genomic test that predicts the risk of distant recurrence fol-
lowing successful surgical resection of early stage, node negative,
estrogen receptor positive b.
Goals: To pilot the use of disease-based cost-effectiveness models
in helping medical policy decision makers to determine the
appropriate place in therapy for a genomic diagnostic test that
is the ﬁrst of many similar products to reach market.
Outcomes items used in the decision: The assessment for the
decision will include evaluating the available body of clinical and
economic evidence. Information related to cost-effectiveness will
be evaluated from the published literature and from evidence
provided from the sponsor company to the health plan, follow-
ing an unsolicited request for this information. The health plan
requested that the evidence package follow the suggested
approach outlined in a 2006 University of Washington, Phar-
maceutical Outcomes Research and Policy Program and Public
Health Genetics Program joint-guidance document, “Evidence
and Transparency Recommendations to Support Coverage and
Reimbursement Decisions for Medical Testing.” The speciﬁc out-
comes to be evaluated for the diagnostic are the clinical effects
and the reliability of the test, economic endpoints related to the
cost of improving overall survival and quality-adjusted survival,
and the sensitivity analyses presented in published economic
models supporting the product. The guidance document suggests
a presentation of clinical information, as well as information on
the costs and consequences and/or cost-effectiveness of new
medical testing technologies.
Implementation Strategy: The case study evaluation process con-
sists of four primary stages. First, a preliminary review of evi-
dence was performed using published literature and the initial
product-related information provided by the sponsor company.
Second, a full evidence support dossier was requested from the
sponsor and will be evaluated by the research team. Third, addi-
tional assessments and sensitivity analyses will be performed to
identify meaningful metrics for product evaluation moving
forward. Fourth, the results are to be presented to the Pharmacy
and Therapeutics Committee for scientiﬁc review, and then to
the Medical Policy Committee, where the ﬁnal decision is made.
The resulting policy will then be implemented through Premera’s
routine medical necessity review process.
Results: The preliminary clinical and economic evaluations
suggest that additional evidence would be helpful to more fully
inform health plans regarding coverage and reimbursement deci-
sions. The sponsor company response to the product information
request (i.e., dossier) is expected to assist the health plan with
evaluating the most recent and complete available Oncotype Dx-
related evidence. The evidence presentation format suggested in
the medical testing guidance allows a product developer the
opportunity to describe and present information related to the
clinical and economic value of their products. An evaluation of
the economic model parameters for which the cost-effectiveness
estimates are most sensitive (e.g., lower-risk recurrence score
patients receiving adjuvant chemotherapy treatment) can provide
ranges of cost-effectiveness related to the expected value of the
diagnostic test, depending on whether the test results inﬂuence
changes in clinical behavior (i.e., forgoing chemotherapy).
Lessons Learned: Clinical-effectiveness and cost-effectiveness
evaluations for medical diagnostic products are increasing in
rigor and in the expectations of health plans for evidence of clin-
ical utility. The value of utilizing higher-priced medical products
for serious illness can be strengthened when diagnostics can
assist with the identiﬁcation of appropriate patient sub-popula-
tions and the likelihood and expected magnitude of clinical and
economic response. However, new diagnostics tend to have less
evidence for evaluation compared to new pharmaceuticals. Pro-
vided that most medical products have limited real world effec-
tiveness data at launch, which may take years to accumulate,
effectiveness modeling can be useful to aid decision-making.
Evaluating the evidence for Oncotype Dx in relation to its clin-
ical and economic net beneﬁt to patients serves as a useful case
for piloting the evidence guidance document and for considering
the health and economic effects of diagnostic testing for difﬁcult
to treat and recurring diseases, such as breast cancer. Standard-
izing the process for and improving the transparency of evidence
evaluation for medical tests should contribute to more efﬁcient
and consistent resource allocation.
